Reply to: Interpreting Circulating Tumor DNA-Guided Risk Stratification After First-Line Therapy
Journal of Clinical Oncology · 01.06.2026 · 44 (16) · 1558-1559
DOI: 10.1200/jco-26-00314 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Oncology, erschienen am 01.06.2026. Verfasst von Joanna A Krupka und 2 weiteren Autor:innen. Beteiligte Einrichtung: Joanna A. Krupka, MB PhD, Cambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom, Department of Haematology, University of…. Die Arbeit nennt 4 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Joanna A. Krupka, MB PhD, Cambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom, Department of Haematology, University of Cambridge, Cambridge, United Kingdom; Alimu Dayimu, PhD, Cambridge Cl…
ORCID-Profile: Joanna A Krupka, Alimu Dayimu, Daniel J Hodson
Zitieren
APA
Krupka, J. A., Dayimu, A., & Hodson, D. J. (2026). Reply to: Interpreting Circulating Tumor DNA-Guided Risk Stratification After First-Line Therapy. Journal of Clinical Oncology, 44(16), 1558-1559. https://doi.org/10.1200/jco-26-00314
Vancouver
Krupka JA, Dayimu A, Hodson DJ. Reply to: Interpreting Circulating Tumor DNA-Guided Risk Stratification After First-Line Therapy. Journal of Clinical Oncology. 2026;44(16):1558-1559. doi:10.1200/jco-26-00314
BibTeX
@article{Krupka2026,
author = {Krupka, Joanna A and Dayimu, Alimu and Hodson, Daniel J},
title = {Reply to: Interpreting Circulating Tumor DNA-Guided Risk Stratification After First-Line Therapy},
journal = {Journal of Clinical Oncology},
year = {2026},
volume = {44},
number = {16},
pages = {1558--1559},
doi = {10.1200/jco-26-00314}
}
EUVIMED